About Satellos Biosciences

We challenge conventions, break scientific ground, and urgently advance drug development, because there’s no time to waste.

Our team is dedicated to developing novel therapeutics for those who live valiantly with Duchenne muscular dystrophy and other degenerative muscle diseases.
At Satellos, we leap past scientific boundaries but are grounded in scientific rigor and data-driven decisions.
About Us
Relentlessly pursuing new
pathways for medicines

Satellos is exploring new pathways for medicines to improve the treatment of degenerative muscle diseases.

Founded on breakthrough research in muscle stem cell biology, the company’s lead drug candidate is an oral, small molecule medicine in development as a potential disease-modifying treatment for Duchenne muscular dystrophy.

The company applies its proprietary discovery platform, called MyoReGenX™, to identify muscle diseases and disorders where muscle tissue is lost or muscle regeneration is defective. With this platform, Satellos then generates novel drug candidates designed to enhance muscle tissue growth and repair to restore muscle function.

The Team
Meet Our
Leadership

Our world renowned team includes leading experts in muscle biology, who have authored landmark studies, as well as industry veterans and experienced drug developers, who have led multiple companies at the edge of science to advance novel therapeutics. Our team brings proven innovation, scientific discipline, and deep experience to advance meaningful therapeutics for patients with degenerative muscle diseases.

Senior Leadership

The Team

Board of Directors

Clinical Advisory Board

Clinical Advisory Board

Discover More